[HTML][HTML] Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
NB Leighl, N Karaseva, K Nakagawa, BC Cho… - European Journal of …, 2020 - Elsevier
Background In the FLAURA trial, osimertinib demonstrated superior progression-free
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study …
H Asahina, K Tanaka, S Morita, M Maemondo… - Clinical Lung Cancer, 2021 - Elsevier
Background Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
Postprogression outcomes for osimertinib versus standard-of-care egfr-tki in patients with previously untreated egfr-mutated advanced non–small cell lung cancer
D Planchard, MJ Boyer, JS Lee, A Dechaphunkul… - Clinical Cancer …, 2019 - AACR
Purpose: In the phase III FLAURA study, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free …
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib significantly improved progression-free …
Tissue and plasma EGFR mutation analysis in the FLAURA trial: Osimertinib versus Comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with …
JE Gray, I Okamoto, V Sriuranpong, J Vansteenkiste… - Clinical cancer …, 2019 - AACR
Purpose: To assess the utility of the cobas EGFR Mutation Test, with tissue and plasma, for
first-line osimertinib therapy for patients with EGFR-mutated (EGFR m; Ex19del and/or …
first-line osimertinib therapy for patients with EGFR-mutated (EGFR m; Ex19del and/or …
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
N Magios, F Bozorgmehr, AL Volckmar… - Therapeutic …, 2021 - journals.sagepub.com
Background: Epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer
(NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted …
(NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted …
A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?
JZ Lin, SK Ma, SX Wu, SH Yu, XY Li - Medicine, 2018 - journals.lww.com
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
the preferred first-line treatment for nonsmall-cell lung cancer (NSCLC) patients with an …
the preferred first-line treatment for nonsmall-cell lung cancer (NSCLC) patients with an …
First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis
H Zhang, J Chen, T Liu, J Dang, G Li - PLoS One, 2019 - journals.plos.org
Background It remains unknown which is the optimal first-line treatment regimen for patients
with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer …
with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer …
[HTML][HTML] Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung …
D Planchard, PH Feng, N Karaseva, SW Kim, TM Kim… - ESMO open, 2021 - Elsevier
Background The phase III FLAURA2 (NCT04035486) study will evaluate efficacy and safety
of first-line osimertinib with platinum–pemetrexed chemotherapy versus osimertinib …
of first-line osimertinib with platinum–pemetrexed chemotherapy versus osimertinib …
Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
JK Rotow, DB Costa, CP Paweletz, MM Awad… - 2020 - ascopubs.org
9507 Background: First-line treatment with an EGFR tyrosine kinase inhibitor (TKI) is
standard of care for patients (pts) with EGFR-mutated NSCLC. The EGFR TKI osimertinib is …
standard of care for patients (pts) with EGFR-mutated NSCLC. The EGFR TKI osimertinib is …
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
Y Ohe, F Imamura, N Nogami, I Okamoto… - Japanese journal of …, 2019 - academic.oup.com
Background The FLAURA study was a multicenter, double-blind, Phase 3 study in which
patients with previously untreated epidermal growth factor receptor mutation-positive …
patients with previously untreated epidermal growth factor receptor mutation-positive …